January 27, 2020
Stand Up To Cancer Announces First-of-Its-Kind Initiative to Increase Diversity in Cancer Clinical Trials
Stand Up To Cancer (SU2C) announced today a groundbreaking initiative to increase minority representation in cancer clinical trials. All future SU2C-supported research grant proposals will now be required to include and address crucial issues related to recruitment and retention of patients from ethnic groups to improve diverse participation in cancer clinical trials. The announcement was made at Stand Up To Cancer’s annual Scientific Summit, which is attended by SU2C’s leadership and 300+ prominent cancer researchers representing each of SU2C’s Dream Teams, Research Teams and individual grants.
Read MoreJanuary 27, 2020
Dr. Laurie Glimcher Named to Stand Up To Cancer Scientific Advisory Committee
Stand Up To Cancer (SU2C) with its Scientific Partner, the American Association of Cancer Research (AACR), announced Laurie H. Glimcher, MD, President and CEO of the Dana-Farber Cancer Institute, Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School as the newest member of the SU2C Scientific Advisory Committee (SAC). Dr. Glimcher was introduced as the SAC’s newest member at the SU2C annual Scientific Summit in Santa Monica.
Read MoreJanuary 13, 2020
Cancer Patients and Survivors Invited to Submit Original Music Compositions to Compete for $2500 USD “Music As Healing” Grants from the Stand Up To Cancer Canada Kate McGarrigle Fund
The Stand Up To Cancer Canada Kate McGarrigle Fund announced today the “Music As Healing” Grant Program, an initiative that will encourage both cancer patients and cancer survivors, to share their cancer journey through original music compositions.
Read MoreOctober 7, 2019
Stand Up To Cancer Congratulates Dr. William G. Kaelin, Jr., SU2C Scientific Leader for 2019 Nobel Prize for Medicine or Physiology
Stand Up To Cancer (SU2C) today congratulated William G. Kaelin, Jr., MD, member of the SU2C Scientific Advisory Committee (SU2C SAC), on receiving the Nobel Prize for Medicine or Physiology for his discovery of how cells sense and adapt to oxygen availability.
Read MoreOctober 3, 2019
TGen-HonorHealth Clinical Trial Shows Tumor Shrinkage in 71 percent of Patients with Late-Stage Pancreatic Cancer
Adding a drug that targets a molecular vulnerability in pancreatic cancer could provide substantial benefit to patients, according to a clinical trial study by the HonorHealth Research Institute and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.
Read MoreSeptember 20, 2019
American Airlines and Stand Up To Cancer Team Up With Hyatt, Universal Orlando Resort to Give Families Affected by Cancer with Weekend to Remember
Today marks the inaugural flight of the American Airlines official Stand Up To Cancer Airbus 321 that features 22,627 names of cancer survivors, patients and those we have lost to cancer. Names were submitted by the public throughout the month of July, all of whom donated $25 or more to have their loved one’s name added to the plane, resulting in more than $825,000 for cancer research.
Read MoreSeptember 16, 2019
Stand Up To Cancer Launches Two Research Teams To Accelerate Clinical Trials for Triple-negative Breast Cancer and Metastatic Prostate Cancer
Stand Up To Cancer (SU2C) is launching teams of experts to lead innovative attacks on two types of cancer that have defied conventional treatment: triple-negative breast cancer (TNBC) in women and metastatic prostate cancer in men.
Read MoreSeptember 11, 2019
Stand Up To Cancer Hails Dr. Dennis J. Slamon, Pioneer In Modern Treatment of Breast Cancer and Leader SU2C Breast Cancer Dream Team
Stand Up To Cancer (SU2C) congratulates Dennis J. Slamon, MD, PhD, leader of the SU2C Breast Cancer Dream Team, on receiving the 2019 Lasker-DeBakey Clinical Medical Research Award for his development of Herceptin, a targeted treatment for HER2-positive breast cancer.
Read MoreAugust 7, 2019
Stand Up To Cancer And Society For Immunotherapy Of Cancer Announce Postdoctroal Convergence Scholar Fellowship Award Recipients
Stand Up To Cancer (SU2C) and the Society for Immunotherapy of Cancer (SITC) today announced five Convergence Scholar Fellowship Award recipients. These early career investigators will work with leading experts in physical and biomedical science to better understand the interplay between the immune system and cancers as they develop.
Read MoreJuly 9, 2019
Make Some Time and Start Something Priceless with Mastercard and Stand Up To Cancer
The opposing All-Star managers are coming together to encourage people to dine out with long lost friends, family, teammates - or really anyone - and remind them to make sure they bring a Mastercard so together we can support cancer research. For the 10th consecutive year, Mastercard is collaborating with SU2C and inviting cardholders to give back through the simple act of dining out.
Read More